Cargando…

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling. Here, we translate these findings into patients by conducting a randomized, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, James L, Lyons, Hannah S, Walker, Jessica K, Yiangou, Andreas, Grech, Olivia, Alimajstorovic, Zerin, Greig, Nigel H, Li, Yazhou, Tsermoulas, Georgios, Brock, Kristian, Mollan, Susan P, Sinclair, Alexandra J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151178/ https://www.ncbi.nlm.nih.gov/pubmed/36907221 http://dx.doi.org/10.1093/brain/awad003

Ejemplares similares

Evaluation of diurnal and postural intracranial pressure employing telemetric monitoring in idiopathic intracranial hypertension
por: Mitchell, James L, et al.
Publicado: (2022)

Emerging themes in idiopathic intracranial hypertension
por: Grech, Olivia, et al.
Publicado: (2020)

Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation
por: Yiangou, Andreas, et al.
Publicado: (2020)

Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache
por: Grech, Olivia, et al.
Publicado: (2022)

Dysregulation of Amino Acid, Lipid, and Acylpyruvate Metabolism in Idiopathic Intracranial Hypertension: A Non-targeted Case Control and Longitudinal Metabolomic Study
por: Alimajstorovic, Zerin, et al.
Publicado: (2022)

Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension
por: Mollan, S. P., et al.
Publicado: (2021)

Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure
por: Grech, Olivia, et al.
Publicado: (2021)

Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension
por: Mollan, Susan P., et al.
Publicado: (2022)

A Neuro-Ophthalmologist’s Guide to Advances in Intracranial Pressure Measurements
por: Mollan, Susan P, et al.
Publicado: (2023)

Determining the role of novel metabolic pathways in driving intracranial pressure reduction after weight loss
por: Alimajstorovic, Zerin, et al.
Publicado: (2023)

Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system
por: Elliot, Laura, et al.
Publicado: (2021)

The Health Economic Evaluation of Bariatric Surgery Versus a Community Weight Management Intervention Analysis from the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT)
por: Aguiar, Magda, et al.
Publicado: (2021)

Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension
por: Westgate, Connar S.J., et al.
Publicado: (2021)

Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension
por: Thaller, Mark, et al.
Publicado: (2021)

Idiopathic Intracranial Hypertension: Evaluation of Admissions and Emergency Readmissions through the Hospital Episode Statistic Dataset between 2002–2020
por: Mollan, Susan P., et al.
Publicado: (2021)

Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension
por: Thaller, M., et al.
Publicado: (2021)

Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial
por: Mollan, Susan P., et al.
Publicado: (2021)

Current Perspectives on Idiopathic Intracranial Hypertension without Papilloedema
por: Mollan, Susan P., et al.
Publicado: (2021)

Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension
por: Yiangou, Andreas, et al.
Publicado: (2020)

11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension
por: Hardy, Rowan S, et al.
Publicado: (2020)

Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom
por: Adderley, Nicola J., et al.
Publicado: (2019)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial
por: Markey, Keira, et al.
Publicado: (2020)

Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: Minimal gain, is it worth the pain?
por: Yiangou, Andreas, et al.
Publicado: (2018)

Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT)
por: Yiangou, Andreas, et al.
Publicado: (2021)

Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
por: Solomon, Thomas P.J., et al.
Publicado: (2022)

Advances in the understanding of headache in idiopathic intracranial hypertension
por: Mollan, Susan P., et al.
Publicado: (2019)

Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey
por: Scotton, William J, et al.
Publicado: (2018)

The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes
por: Thaller, Mark, et al.
Publicado: (2022)

Evaluation and management of adult idiopathic intracranial hypertension
por: Mollan, Susan P, et al.
Publicado: (2018)

Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension
por: Westgate, Connar S J, et al.
Publicado: (2022)

The expanding burden of idiopathic intracranial hypertension
por: Mollan, Susan P., et al.
Publicado: (2018)

Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension
por: Aojula, Anuriti, et al.
Publicado: (2018)

Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
por: Li, Yazhou, et al.
Publicado: (2019)

Visual Field Pointwise Analysis of the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT)
por: Mollan, Susan P., et al.
Publicado: (2023)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension
por: Mitchell, James L., et al.
Publicado: (2019)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Reviewing the Recent Developments in Idiopathic Intracranial Hypertension
por: Virdee, Jasvir, et al.
Publicado: (2020)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gvm4m85an544rjb8ftsmt10csu